Please wait while the formulary information is being retrieved.
STAVUDINE (STAVUDINE)
- HIV infection
15 mg capsule
- 2 capsules (30 mg) by oral route every 12 hours
20 mg capsule
- 2 capsules (40 mg) by oral route every 12 hours
30 mg capsule
- 1 capsule (30 mg) by oral route every 12 hours
40 mg capsule
- 1 capsule (40 mg) by oral route every 12 hours
HIV infection
- 1 capsule (15 mg) by oral route every 12 hours
- 1 capsule (20 mg) by oral route every 12 hours
- 2 capsules (30 mg) by oral route every 12 hours
- 1 capsule (30 mg) by oral route every 12 hours
- 2 capsules (40 mg) by oral route every 12 hours
- 1 capsule (40 mg) by oral route every 12 hours
- None
Contraindicated
- abacavir-lamivudine-zidovudine
- Adriamycin
- Adriamycin Pfs
- Combivir
- Copegus
- didanosine
- Doxil
- doxorubicin
- doxorubicin HCl peg-liposomal
- lamivudine-zidovudine
- Lipodox
- Lipodox 50
- Moderiba
- Moderiba Dose Pack
- Rebetol
- Retrovir
- Ribapak Dose Pack
- Ribasphere
- Ribatab Dose Pack
- ribavirin
- Trizivir
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
- Virazole
- zidovudine
Severe
Moderate
- Diskets
- Dolophine
- methadone
- Methadone Intensol
- Methadose
- Lactating mother
- Lactic acidosis
- Steatosis of liver
Contraindicated
- Acute pancreatitis
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Chronic pancreatitis
- Peripheral neuropathy
Severe
Moderate
- Alcoholism
- Diabetes mellitus
- Disease of liver
- Kidney disease with likely reduction in GFR
- Obesity
STAVUDINE (STAVUDINE)
- HIV infection
- Skin rash
- Diarrhea
- Headache disorder
- Lipodystrophy associated with HIV
- Nausea
- Peripheral neuropathy
- Vomiting
More Frequent
Severe
Less Severe
- Myalgias
- Anorexia
- Dysesthesia
- Gastrointestinal irritation
- General weakness
- Hypesthesia
- Insomnia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute pancreatitis
- Anemia
- Diabetes mellitus
- Hepatic failure
- Hepatitis
- Hyperglycemia
- Lactic acidosis
- Leukopenia
- Macrocytosis
- Steatosis of liver
- Thrombocytopenic disorder
Less Severe
- Acute abdominal pain
- Chills
- Fever
- Muscle weakness
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Stavudine
- Severity Level:
2
- Additional Notes: Caution; fatal lactic acidosis reported when used with other antiretrovirals
Contraindicated
Stavudine
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Rarely, stavudine has caused a severe (sometimes fatal) pancreas problem (pancreatitis) when used alone or with other HIV medicines. Immediately tell your doctor if you develop symptoms of pancreatitis (persistent nausea/vomiting, stomach/abdominal/back pain). Rarely, stavudine has caused a severe (sometimes fatal) liver and blood problem (lactic acidosis).<br /><br />Tell your doctor right away if you develop symptoms of liver problems (persistent nausea, stomach/abdominal pain, dark urine, yellowing eyes/skin) or lactic acidosis (rapid breathing, drowsiness, muscle aches). Pregnant women with HIV may be more likely to have this problem. Do not use stavudine with didanosine because of the increased risk of serious side effects.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool